Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18666109 | SALTS AND SOLID FORMS OF (R)-1-(5-METHOXY-1H-INDOL-1-YL)-N,N-DIMETHYLPROPAN-2-AMINE | May 2024 | March 2025 | Allow | 10 | 0 | 0 | Yes | No |
| 18437502 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | February 2024 | March 2025 | Allow | 13 | 0 | 1 | No | No |
| 18436024 | OX2R Compounds | February 2024 | April 2025 | Abandon | 14 | 0 | 1 | No | No |
| 18434560 | Cyclic Thiol Prodrugs | February 2024 | May 2025 | Abandon | 15 | 0 | 1 | No | No |
| 18422175 | INDOLOCARBAZOLE ANALOGS OF STAUROSPORINE AND METHODS OF SYNTHESIS THEREOF | January 2024 | August 2024 | Allow | 7 | 0 | 0 | Yes | No |
| 18422793 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | January 2024 | May 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18543691 | SYNTHETIC ROUTE TO 2,2',6,6'-TETRAISOPROPYL-4,4'-DIIODOAZOBENZENE VIA HOMO-OXIDATIVE CROSS-COUPLING OF ARYL DIAZONIUM SALT USING CU-CATALYZED SANDMEYER-STYLE REACTION | December 2023 | March 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18540206 | PHOTOSWITCHABLE ISOMERIZATION OF STERICALLY HINDERED 2,2',6,6'-TETRAISOPROPYL-4,4'-DIETHYNYLAZOBENZENE | December 2023 | March 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18534171 | SYNTHETIC ROUTE TO 2,2'-DIMETHYL-4,4'-DIIODOAZOBENZENE VIA HOMO-OXIDATIVE CROSS-COUPLING OF ARYL DIAZONIUM SALT USING CU-CATALYZED SANDMEYER-STYLE REACTION | December 2023 | March 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18526983 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | December 2023 | April 2025 | Allow | 17 | 1 | 1 | No | No |
| 18516091 | TROPOMYOSIN-RELATED KINASE (trk) INHIBITORS | November 2023 | February 2025 | Allow | 14 | 1 | 0 | Yes | No |
| 18388084 | PROTEIN KINASE MKK4 INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | November 2023 | December 2024 | Allow | 13 | 2 | 0 | Yes | No |
| 18384685 | 4-(2,4,5-TRIS(4-CHLOROPHENYL)-1H-IMIDAZOL-1-YL)BENZOIC ACID AS AN ANTIMICROBIAL COMPOUND | October 2023 | January 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18383896 | Pyridinylcyanoguanidine Derivative and Use Thereof | October 2023 | June 2024 | Allow | 8 | 0 | 0 | Yes | No |
| 18490942 | BENZOMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | October 2023 | February 2025 | Allow | 16 | 1 | 0 | Yes | No |
| 18488972 | 6-(5-(3-FLUOROPHENYL)-4-PHENYL-4H-1,2,4-TRIAZOL-3-YLTHIO)HEXANOIC ACID AS AN ANTIMICROBIAL COMPOUND | October 2023 | January 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18486487 | CRYSTALLINE FORMS AND METHODS OF PRODUCING CRYSTALLINE FORMS OF A COMPOUND | October 2023 | October 2024 | Allow | 12 | 1 | 0 | No | No |
| 18379609 | 4-METHOXY-N'-(2-(5-PHENYL-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)BENZIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | October 2023 | December 2023 | Allow | 2 | 0 | 0 | Yes | No |
| 18483292 | 7-(4-((5-(2-BROMOBENZYLIDENEAMINO)-2-THIOXO-1,3,4-THIADIAZOL-3(2H)-YL)METHYL)PIPERAZIN-1-YL)-1-CYCLOPROPYL-6-FLUORO-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID AS AN ANTI-INFLAMMATORY COMPOUND | October 2023 | January 2024 | Allow | 3 | 1 | 0 | No | No |
| 18472101 | ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS | September 2023 | March 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18465497 | DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | September 2023 | April 2025 | Allow | 19 | 2 | 1 | Yes | No |
| 18354362 | ANTIVIRAL COMPOUNDS | July 2023 | November 2024 | Allow | 16 | 0 | 0 | No | No |
| 18350246 | 2-Methyl-Quinazolines | July 2023 | January 2025 | Abandon | 18 | 0 | 1 | No | No |
| 18259578 | METHOD OF SYNTHESIZING INDOLE COMPOUNDS | June 2023 | March 2025 | Allow | 20 | 2 | 1 | Yes | No |
| 18339506 | STING AGONISTIC COMPOUND | June 2023 | August 2024 | Allow | 14 | 1 | 0 | No | No |
| 18338096 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | June 2023 | December 2024 | Allow | 18 | 1 | 0 | No | No |
| 18337329 | ANTI-INFLUENZA VIRUS PYRIMIDINE DERIVATIVES | June 2023 | February 2025 | Allow | 20 | 2 | 0 | Yes | No |
| 18211134 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | June 2023 | December 2024 | Abandon | 18 | 0 | 1 | No | No |
| 18335803 | INHIBITORS OF MEK KINASE | June 2023 | June 2024 | Allow | 12 | 0 | 0 | Yes | No |
| 18202072 | METHODS AND FORMULATIONS FOR TREATMENT OF SPINOBULBAR MUSCULAR ATROPHY | May 2023 | December 2024 | Abandon | 19 | 0 | 1 | No | No |
| 18322890 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | May 2023 | July 2024 | Allow | 14 | 2 | 0 | No | No |
| 18144890 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | May 2023 | May 2024 | Allow | 12 | 1 | 0 | No | No |
| 18142842 | CONDENSED HETEROCYCLIC DERIVATES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES | May 2023 | September 2024 | Allow | 16 | 2 | 0 | No | No |
| 18307911 | METHODS OF PREPARING GLUFOSINATE | April 2023 | December 2024 | Allow | 19 | 2 | 0 | Yes | No |
| 18303264 | AMINOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | April 2023 | February 2025 | Abandon | 22 | 0 | 1 | No | No |
| 18301179 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | April 2023 | February 2024 | Allow | 10 | 2 | 1 | Yes | No |
| 18125961 | INHIBITORS OF THE WNT/BETA-CATENIN PATHWAY | March 2023 | May 2025 | Allow | 25 | 3 | 1 | No | No |
| 18179211 | TLR7/8 ANTAGONISTS AND USES THEREOF | March 2023 | December 2024 | Abandon | 21 | 1 | 1 | No | No |
| 18177408 | SALTS AND SOLID FORMS OF (R)-1-(5-METHOXY-1H-INDOL-1-YL)-N,N-DIMETHYLPROPAN-2-AMINE | March 2023 | July 2024 | Allow | 17 | 1 | 0 | Yes | No |
| 18175074 | INHIBITORS OF MEK KINASE | February 2023 | May 2023 | Allow | 3 | 0 | 0 | Yes | No |
| 18108785 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | February 2023 | May 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18166689 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | February 2023 | February 2024 | Allow | 12 | 1 | 1 | Yes | No |
| 18099760 | PYRIDINIUM SALTS AND METHODS OF USE | January 2023 | August 2024 | Allow | 19 | 1 | 1 | Yes | No |
| 18147178 | Cyclic Thiol Prodrugs | December 2022 | November 2023 | Allow | 11 | 1 | 1 | Yes | No |
| 18082847 | CRYSTALLINE AND SALT FORMS OF PPAR AGONIST COMPOUNDS | December 2022 | October 2023 | Allow | 10 | 1 | 0 | No | No |
| 18080723 | Pyridinylcyanoguanidine Derivative and Use Thereof | December 2022 | November 2023 | Allow | 11 | 1 | 1 | No | No |
| 18074219 | Antiviral Compounds | December 2022 | February 2024 | Abandon | 14 | 1 | 0 | No | No |
| 18074168 | DERIVATIVES OF PORPHYRINS, THEIR PROCESS OF PREPARATION AND THEIR USE FOR TREATING VIRAL INFECTIONS | December 2022 | April 2024 | Abandon | 16 | 1 | 0 | No | No |
| 17988753 | SALTS AND SOLID FORMS OF (R)-1-(5-METHOXY-1H-INDOL-1-YL)-N,N-DIMETHYLPROPAN-2-AMINE | November 2022 | July 2024 | Abandon | 20 | 2 | 0 | No | No |
| 17998355 | PYRIDINE DERIVATIVE AND APPLICATION THEREOF | November 2022 | June 2025 | Allow | 31 | 0 | 0 | Yes | No |
| 18050883 | IRAK4 DEGRADERS AND SYNTHESIS THEREOF | October 2022 | August 2024 | Allow | 21 | 1 | 1 | Yes | No |
| 17971547 | OX2R Compounds | October 2022 | September 2023 | Allow | 11 | 2 | 1 | Yes | No |
| 17919483 | GPR52 MODULATORS AND METHODS OF USE | October 2022 | May 2025 | Allow | 31 | 0 | 0 | Yes | No |
| 18046303 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | October 2022 | December 2023 | Allow | 14 | 0 | 1 | Yes | No |
| 18045647 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | October 2022 | October 2024 | Allow | 24 | 1 | 1 | No | No |
| 17938890 | RAS INHIBITORS | October 2022 | August 2024 | Allow | 22 | 1 | 1 | No | No |
| 17947593 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | September 2022 | January 2024 | Abandon | 16 | 2 | 1 | No | No |
| 17946587 | ANTIBACTERIAL COMPOUNDS | September 2022 | August 2023 | Allow | 11 | 1 | 1 | Yes | No |
| 17894412 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | August 2022 | January 2024 | Allow | 17 | 1 | 1 | Yes | No |
| 17798637 | METHOD FOR PRODUCING METHYLENE DISULFONATE COMPOUND | August 2022 | September 2024 | Allow | 25 | 2 | 0 | Yes | No |
| 17883350 | TROPOMYOSIN-RELATED KINASE (trk) INHIBITORS | August 2022 | July 2023 | Allow | 11 | 1 | 0 | Yes | No |
| 17427778 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING MIDDLE EAST RESPIRATORY SYNDROME | July 2022 | April 2025 | Allow | 44 | 0 | 0 | Yes | No |
| 17795778 | COMPOUNDS AND USES THEREOF | July 2022 | April 2025 | Allow | 33 | 0 | 0 | Yes | No |
| 17815064 | METHOD FOR PRODUCING DIFLUOROMETHYL-SUBSTITUTED AROMATIC HETEROCYCLIC COMPOUND | July 2022 | June 2025 | Allow | 34 | 0 | 1 | No | No |
| 17861740 | CARBON CAPTURE, STORAGE, AND RECYCLING COMPOSITIONS | July 2022 | March 2024 | Allow | 20 | 0 | 1 | Yes | No |
| 17862290 | 2-SUBSTITUTED AMINO-NAPHTH (1,2-D) IMIDAZOL-5-ONE COMPOUNDS OF PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | July 2022 | December 2024 | Allow | 29 | 2 | 0 | No | No |
| 17791852 | MULTI-AZIRIDINE COMPOUND | July 2022 | June 2025 | Allow | 36 | 1 | 0 | Yes | No |
| 17856915 | SUBSTITUTED 4,6-DIHYDROSPIRO[[1,2,3]TRIAZOLO[4,5-B]PYRIDINE-7,3'-INDOLINE]-2',5(3H)-DIONE ANALOGUES | July 2022 | April 2024 | Allow | 22 | 1 | 1 | Yes | No |
| 17855336 | MK2 DEGRADERS AND USES THEREOF | June 2022 | June 2024 | Allow | 23 | 2 | 1 | Yes | No |
| 17845469 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | June 2022 | October 2023 | Allow | 16 | 1 | 1 | Yes | No |
| 17787522 | CARBACYCLIC PHOSPHATIDIC ACID COMPOUND | June 2022 | December 2023 | Allow | 18 | 1 | 0 | No | No |
| 17786593 | PHOSPHATE DERIVATIVES OF RORGAMMA MODULATORS AND USES THEREOF | June 2022 | April 2025 | Allow | 34 | 0 | 0 | Yes | No |
| 17786159 | AMINO DITHIOPERACID THIOESTER COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | June 2022 | December 2024 | Allow | 30 | 1 | 0 | No | No |
| 17835106 | BICYCLIC HETEROARYL DERIVATIVES AND PREPARATION AND USES THEREOF | June 2022 | December 2022 | Allow | 7 | 0 | 0 | No | No |
| 17826711 | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | May 2022 | October 2023 | Allow | 17 | 1 | 1 | Yes | No |
| 17826479 | PYRAZOL-3-ONES THAT ACTIVATE PRO-APOPTOTIC BAX | May 2022 | December 2024 | Abandon | 31 | 2 | 1 | No | No |
| 17780052 | CANNABINOID DERIVATIVES | May 2022 | April 2025 | Allow | 34 | 1 | 1 | Yes | No |
| 17755852 | NOVEL DERIVATIVES HAVING 1,2,3,4-TETRAHYDRONAPHTHALENE MOIETY OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | May 2022 | March 2025 | Allow | 35 | 0 | 0 | Yes | No |
| 17719653 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | April 2022 | March 2024 | Allow | 23 | 1 | 1 | Yes | No |
| 17765856 | CANNABINOID DERIVATIVES | April 2022 | August 2024 | Allow | 28 | 2 | 1 | Yes | No |
| 17762771 | INDAZOLE CARBOXAMIDES AS KINASE INHIBITORS | March 2022 | November 2024 | Allow | 32 | 0 | 0 | Yes | No |
| 17699944 | SUBSTITUTED INDOLE COMPOUNDS | March 2022 | April 2023 | Allow | 12 | 0 | 1 | Yes | No |
| 17698283 | REDUCING AGENTS AND USES THEREOF | March 2022 | April 2024 | Allow | 24 | 2 | 1 | Yes | No |
| 17698289 | CONDENSED HETEROCYCLIC DERIVATES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES | March 2022 | February 2023 | Allow | 11 | 1 | 0 | No | No |
| 17698924 | Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans | March 2022 | October 2024 | Allow | 31 | 4 | 0 | No | No |
| 17760830 | 2,5-DIMERCAPTO-1,3,4-THIADIAZOLE (DMTD) DERIVATIVES | March 2022 | January 2025 | Allow | 34 | 1 | 0 | Yes | No |
| 17688709 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | March 2022 | July 2023 | Allow | 16 | 1 | 1 | Yes | No |
| 17679075 | 3,6-METHANO-1H-PYRROLO[3,2-b]PYRIDINE AND 3,6-METHANO-1H-PYRROLO[3,2-c]PYRIDINE COMPOUNDS AND MEDICAMENTS USING SAME | February 2022 | May 2023 | Allow | 15 | 1 | 1 | Yes | No |
| 17637365 | Nucleoside Prodrugs and Uses Related Thereto | February 2022 | October 2023 | Abandon | 19 | 1 | 1 | Yes | No |
| 17636701 | PYRIDAZINE COMPOUND AND HERBICIDE | February 2022 | February 2025 | Allow | 36 | 0 | 0 | Yes | No |
| 17634313 | Reduction of the odor of monothiocarbonate compounds by addition of oxidants | February 2022 | December 2024 | Allow | 34 | 1 | 0 | Yes | No |
| 17629186 | METHOD FOR PRODUCING CYCLIC DISULFONIC ACID ESTER COMPOUND | January 2022 | July 2023 | Allow | 18 | 0 | 0 | Yes | No |
| 17628980 | COMPOUND, COMPOSITION, FILM, LAMINATE, AND DISPLAY DEVICE | January 2022 | November 2023 | Allow | 22 | 1 | 1 | No | No |
| 17629167 | METHOD FOR PRODUCING METHYLENE DISULFONATE COMPOUND | January 2022 | August 2024 | Allow | 31 | 2 | 0 | No | No |
| 17628312 | COLOR MATERIAL COMPOUND | January 2022 | November 2024 | Allow | 34 | 0 | 0 | Yes | No |
| 17576410 | AMINOPYRIMIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | January 2022 | January 2024 | Allow | 24 | 2 | 0 | Yes | No |
| 17576089 | FUSED IMIDAZO-PIPERIDINE JAK INHIBITORS | January 2022 | January 2023 | Allow | 12 | 1 | 0 | No | No |
| 17626519 | CANNABINOID DERIVATIVES | January 2022 | February 2024 | Allow | 25 | 1 | 1 | Yes | No |
| 17626518 | CANNABINOID DERIVATIVES | January 2022 | November 2024 | Allow | 34 | 3 | 1 | Yes | No |
| 17570536 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | January 2022 | March 2023 | Allow | 14 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner STOCKTON, LAURA LYNNE.
With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 31.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner STOCKTON, LAURA LYNNE works in Art Unit 1626 and has examined 2,061 patent applications in our dataset. With an allowance rate of 73.3%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 22 months.
Examiner STOCKTON, LAURA LYNNE's allowance rate of 73.3% places them in the 29% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by STOCKTON, LAURA LYNNE receive 1.46 office actions before reaching final disposition. This places the examiner in the 34% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by STOCKTON, LAURA LYNNE is 22 months. This places the examiner in the 79% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +38.2% benefit to allowance rate for applications examined by STOCKTON, LAURA LYNNE. This interview benefit is in the 88% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 30.7% of applications are subsequently allowed. This success rate is in the 53% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 55.6% of cases where such amendments are filed. This entry rate is in the 78% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 36.4% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 33% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 85.4% of appeals filed. This is in the 76% percentile among all examiners. Of these withdrawals, 82.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 49.7% are granted (fully or in part). This grant rate is in the 59% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 11.8% of allowed cases (in the 97% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.2% of allowed cases (in the 58% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.